Leading the Way in Life Science Technologies

GEN Exclusives

More »

GEN News Highlights

More »
Jan 16, 2007

Neurobiological Technologies Collects $4M for Xerecept Rights

  • Neurobiological Technologies (NTI)  received $4 million from Celtic Pharmaceutical  as the final noncontingent payment for worldwide rights to Celtic Pharma for Xerecept®, a Phase III clinical compound being studied for the treatment of peritumoral brain edema.

    With this final payment, NTI will have received a total of $33 million in guaranteed payments for the sale of Xerecept. NTI will also receive up to $15 million in additional payments if Xerecept meets certain regulatory milestones. NTI is serving as the CRO for the Phase III Xerecept trials and will receive a share of profits in the U.S. and royalties in other international markets if Xerecept ultimately receives regulatory approval and is commercialized.



Be sure to take the GEN Poll

Scientifically Studying Ecstasy

MDMA (commonly known as the empathogen “ecstasy”) is classified as a Schedule 1 drug, which is reserved for compounds with no accepted medical use and a high abuse potential. Two researchers from Stanford, however, call for a rigorous scientific exploration of MDMA's effects to identify precisely how the drug works, the data from which could be used to develop therapeutic compounds.

Do you agree that ecstasy should be studied for its potential therapeutic benefits?

More »